Lab
Optima Medical Center INC
Optima Medical Center INC was paid $1.94M by Medicaid between Jul 2022 and Nov 2024, across 11 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 36% of everything it billed.
33Billing provider infoOPTIMA MEDICAL CENTER INC
CHICAGO, IL 60640
CHICAGO, IL 60640
33aNPI1902548647assigned 04/12/2022
33bProvider typeClinical Medical Laboratory
28Total paid$1.94M
24GClaims34,982
24DCodes billed11
24AFirst – last monthJul 2022 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#60 of 235
Median peer was paid$123K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 4,445 | $177K | |
| 2023 | 21,361 | $1.23M | |
| 2024incomplete | 9,176 | $529K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 36% | 6,033 | 1,463 | $707K |
| 0240U | 27% | 4,520 | 2,378 | $524K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.8% | 2,742 | 1,662 | $189K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 9.5% | 6,101 | 3,401 | $185K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.9% | 2,080 | 1,222 | $114K |
| 99000 | 3.7% | 3,517 | 1,911 | $72K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.0% | 2,677 | 1,629 | $58K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.8% | 2,435 | 1,657 | $55K |
| 87428 | 1.3% | 599 | 453 | $26K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 4,220 | 1,048 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 58 | 40 | $193.75 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPASHA, IMTIYAZ (OWNER)